Cortisol-Metabolizing Enzymes in Polycystic Ovary Syndrome

被引:17
作者
Blumenfeld, Zeev [1 ,2 ]
Kaidar, Gabi [3 ]
Zuckerman-Levin, Nehama [3 ]
Dumin, Elena [4 ]
Knopf, Carlos [4 ]
Hochberg, Ze'ev [2 ]
机构
[1] Technion Israel Inst Technol, Dept Obstet & Gynecol, Sect Reprod Endocrinol, Rambam Hlth Care Campus, Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Family Fac Med, Haifa, Israel
[3] Technion Israel Inst Technol, Meyer Childrens Hosp, Div Pediat Endocrinol, Haifa, Israel
[4] Rambam Hlth Care Campus, Dept Clin Biochem, Haifa, Israel
来源
CLINICAL MEDICINE INSIGHTS-REPRODUCTIVE HEALTH | 2016年 / 10卷
关键词
polycystic ovary syndrome; glucocorticoid; adrenal gland;
D O I
10.4137/CMRH.S35567
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The aim of this study was to assess the activity of cortisol-metabolizing enzymes in women with polycystic ovary syndrome (PCOS), using a fully quantitative gas chromatography/mass spectrometry (GCMS) method. DESIGN: We investigated the glucocorticoid degradation pathways that include 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type 1, 5 alpha-reductase (5 alpha-R) and 5 beta-reductase (5 beta-R), 3 alpha-hydroxysteroid dehydrogenase, and 20 alpha -and 20 beta-hydroxysteroid dehydrogenase (20 alpha-HSD and 20 beta-HSD, respectively) in young nonobese women with PCOS, using a fully quantitative GCMS method. SETTING: This study was conducted in a tertiary referral hospital in Israel. PATIENTS: This study group consisted of 13 young women, aged 20.1 +/- 2.8 years (mean +/- SD), with the body mass index (BMI) of 22.6 +/- 3.7 kg/m(2), diagnosed with PCOS according to the Rotterdam criteria. The control group consisted of 14 healthy young women matched for weight, height, and BMI. INTERVENTIONS: Urine samples were analyzed using GCMS. We measured urinary steroid metabolites that represent the products and substrates of the study enzymes and calculated the product/substrate ratios to represent enzyme activity. MAIN OUTCOME MEASURES: The calculation of enzymatic activity, based on glucocorticoid degradation metabolites, was done by GCMS in PCOS vs. controls. RESULTS: All glucocorticoid degradation metabolites were higher in the PCOS group than in controls. Of the adrenal enzymes, the activities of 21-hydroxylase and 17 alpha-hydroxylase were reduced, whereas the activity of 17,20-lyase was enhanced in PCOS. Of the degradation enzymes, the activity of 11 beta-HSD type 1 was reduced in women with PCOS only when calculated from cortoles and cortolones ratios. The activities of 5 alpha-R/5 beta-R were increased only when calculating the 11-hydroxy metabolites of androgens. The activity of 20a-HSD was elevated in the patients with PCOS and its relation with the substrate levels was lost. CONCLUSIONS: We confirm PCOS association with low 21-hydroxylase activity. PCOS is associated with dysregulation in glucocorticoid degradation. The activity of 5 alpha-R is enhanced only through the backdoor pathway. Marked increase in the activity of 20 alpha-HSD suggests a hitherto unknown derangement in PCOS.
引用
收藏
页数:5
相关论文
共 27 条
  • [1] Alterations of folliculogenesis in women with polycystic ovary syndrome
    Analia Sander, Valeria
    Belen Hapon, Maria
    Sicaro, Laura
    Pedro Lombardi, Eduardo
    Alma Jahn, Graciela
    Beatriz Motta, Alicia
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 124 (1-2) : 58 - 64
  • [2] The backdoor pathway to dihydrotestosterone
    Auchus, RJ
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (09) : 432 - 438
  • [3] Overdiagnosis of 21-hydroxylase late onset congenital adrenal hyperplasia: Correlation of corticotropin test and human leukocyte antigen typing
    Avivi, I
    Pollack, S
    Gideoni, O
    Linn, S
    Blumenfeld, Z
    [J]. FERTILITY AND STERILITY, 1996, 66 (04) : 557 - 563
  • [4] The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selina F.
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 456 - 488
  • [5] Defining polycystic ovary syndrome
    Balen, Adam
    Homburg, Roy
    Franks, Stephen
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338
  • [6] Chin D, 2000, J PEDIATR ENDOCR MET, V13, P253
  • [7] Human 20α-hydroxysteroid dehydrogenase:: Crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids
    Couture, JF
    Legrand, P
    Cantin, L
    Luu-The, V
    Labrie, F
    Breton, R
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 331 (03) : 593 - 604
  • [8] Beyond adrenal and ovarian androgen generation:: Increased peripheral 5α-reductase activity in women with polycystic ovary syndrome
    Fassnacht, M
    Schlenz, N
    Schneider, SB
    Wudy, SA
    Allolio, B
    Arlt, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) : 2760 - 2766
  • [9] Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome
    Gambineri, Alessandra
    Vicennati, Valentina
    Genghini, Silvia
    Tomassoni, Federica
    Pagotto, Uberto
    Pasquali, Renato
    Walker, Brian R.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) : 2295 - 2302
  • [10] Adrenal 20α-hydroxysteroid dehydrogenase in the mouse catabolizes progesterone and 11-deoxycorticosterone and is restricted to the X-zone
    Hershkovitz, Liat
    Beuschlein, Felix
    Klammer, Steffen
    Krup, Margalit
    Weinstein, Yacob
    [J]. ENDOCRINOLOGY, 2007, 148 (03) : 976 - 988